In this episode focused on first-line MS treatments, Dr. Williams poses the practical question: when a newly diagnosed, treatment-naive patient with relapsing-remitting MS sits across from you, what guides your treatment recommendation?
How MS therapy choices balance patient preference, payer coverage, dosing convenience, and family planning as high-efficacy options expand.
The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]
Experts weigh CIDP care: IVIG limits, emerging therapies, early-yet-accurate diagnosis, objective response checks, and screening for paraproteins.
Epileptologist Sam Amin, MD, reviews the safety and tolerability findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, including treatment-emergent adverse events and the absence of major cardiovascular complications.
The associate professor of neurology at Northwestern University Feinberg School of Medicine reviewed key aspects of the 2026 AHA/ASA stroke guidelines in acute ischemic stroke. [WATCH TIME: 5 minutes]
The associate professor of neurology at Mayo Clinic College of Medicine highlighted emerging migraine targets, repurposed therapies, and growing emphasis on patient-reported outcomes beyond monthly migraine days. [WATCH TIME: 3 minutes]
The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]
The discussion opens with a broad overview of seizure burden in grade 2 IDH-mutant glioma, highlighting how epilepsy affects quality of life, long-term disease management, and day-to-day functioning throughout the disease course.
At ATMRD 2026, the director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]
A Parkinson’s patient reveals how off times, med trials and a continuous pump strain family life—and how advocacy brings stability.
At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]
A Parkinson’s patient explains how a daily apomorphine pump smooths off time, cuts levodopa, and restores confidence, work, and social life.
In this episode, panelists explore the question of "MS Treatment Strategy: High-Efficacy Therapy vs. Escalation Approach." Dr. Williams frames the central question: with earlier MS diagnoses now possible, how has treatment philosophy shifted? The traditional "start low, go slow" escalation model has given way to a high-efficacy-first approach for many clinicians.
Welcome back to another Neurology Live Peer Exchange series. In this episode titled "Evolving MS Diagnostic Criteria: 2024 McDonald Criteria and What's New," moderator Dr. Mitzi Joi Williams discusses multiple sclerosis with Dr. Stephen Krieger.
The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]
In this final episode, Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss why neurologists should stay informed on stem cell medicine and the broader implications of regenerative therapies across neurology.
Neurology News Network for the week ending June 6th, 2026. [WATCH TIME: 5 minutes]
The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]
Clinicians explain long-term CIDP care: set expectations for ongoing therapy, taper safely, reassess often, and add rehab, mental health, nutrition.
Learn how clinicians partner with CIDP patients to choose IVIG, steroids or SCIG, set expectations, and tailor treatment to real life.
Neurologists Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss how stem cell therapies may differ from existing Parkinson disease treatments and the potential benefits of dopamine cell replacement.
Sam Amin, MD, reviews the primary and secondary efficacy findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting meaningful reductions in seizure burden and improvements in global functioning measures.
Richard Nowak, MD, MS, discusses remaining questions surrounding inebilizumab in generalized myasthenia gravis, including long-term durability, biomarker development, and the need for real-world and expanded population data.
Mitzi Joi Williams, MD, sits down with sleep specialist Shantel Branson, MD, to discuss how sleep impacts brain health, memory, mood, and long-term neurologic well-being.
At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]
The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]
Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, examine the expanding clinical trial landscape for stem cell therapies in Parkinson disease and the programs leading development efforts.
The research neuropsychologist at Mount Sinai Rehabilitation Hospital outlined hallmark patterns of cognitive impairment in multiple sclerosis at the 2026 CMSC Annual Meeting. [WATCH TIME: 6 minutes]
From patient questions to clinical trial referrals, this episode highlights practical strategies for counseling individuals interested in stem cell-based therapies for Parkinson disease.